Compare CVRX & TMCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVRX | TMCI |
|---|---|---|
| Founded | 2000 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.0M | 174.6M |
| IPO Year | 2021 | 2021 |
| Metric | CVRX | TMCI |
|---|---|---|
| Price | $7.31 | $2.42 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 5 |
| Target Price | ★ $13.17 | $4.21 |
| AVG Volume (30 Days) | 371.4K | ★ 707.1K |
| Earning Date | 02-04-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $55,969,000.00 | ★ $218,879,000.00 |
| Revenue This Year | $11.91 | $3.30 |
| Revenue Next Year | $15.28 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18.44 | 7.90 |
| 52 Week Low | $4.30 | $2.36 |
| 52 Week High | $17.78 | $10.79 |
| Indicator | CVRX | TMCI |
|---|---|---|
| Relative Strength Index (RSI) | 50.09 | 35.40 |
| Support Level | $6.96 | $2.56 |
| Resistance Level | $6.09 | $2.75 |
| Average True Range (ATR) | 0.81 | 0.17 |
| MACD | 0.17 | 0.00 |
| Stochastic Oscillator | 60.17 | 0.76 |
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.